Bayer's $7.25B Roundup Deal: Litigation Exposure and Provisioning Lessons
A Missouri judge approved Bayer's Roundup class settlement on 20 November 2026. We dissect the gap between the headline cap, the booked provision and the cash outflow, and derive a prioritised playbook for managing mass-tort exposure.
Executive summary
On 20 November 2026, a Missouri judge approved Bayer's proposed nationwide class settlement covering current and future Roundup claims alleging non-Hodgkin lymphoma [Newsquawk] [Euronext]. The headline figure is up to $7.25 billion, paid through declining, capped annual payments over as many as 21 years [Bayer].
The core lesson for finance, legal and risk teams is that three different numbers describe the same exposure, and they must not be confused:
- The nominal cap: up to $7.25 billion, spread over up to 21 years Bayer–Monsanto announcement.
- The accounting provision: Bayer said total litigation provisions and liabilities would rise from €7.8 billion (including €6.5 billion for glyphosate) at 30 September 2025 to €11.8 billion (including €9.6 billion for glyphosate), subject to final audit [Bayer via BusinessWire].
- The near-term cash burden: Bayer's first estimate of litigation-related payouts in 2026 was approximately €5 billion, leading it to expect negative free cash flow for the year [Bayer via BusinessWire].
The settlement gives Bayer a ceiling on a large part of its U.S. Roundup exposure, but not an end to it. Excluded federal proceedings, appeals and separate legal questions remain open [Euronext].
Methodology
This analysis is reproducible with four steps and a stated evidence hierarchy.
Step 1 - Separate three metrics. For any mass-tort settlement, record (a) the nominal cap, (b) the booked provision and (c) the projected cash outflow by year. They differ in scope, timing and valuation basis.
Step 2 - Prefer company and court disclosures. Company announcements and court-approval reports take precedence over secondary commentary. Where sources diverge, we flag it and cite both.
Step 3 - Build a reference series. We assemble the provision series Bayer itself published and compare successive reference dates.
Step 4 - Stress the residual exposure. We list what the settlement does not cover (excluded proceedings, appeals, nonparticipation, separate legal questions) and rank the resulting risks.
Limits of the evidence. The official-institution results retrieved for this study (EU institutions and SEC archives) do not independently verify the $7.25 billion figure or contain Bayer's Roundup provision methodology; the SEC items retrieved concern other matters and cannot be attributed to Roundup [SEC filing] [SEC archive]. The settlement terms below therefore rest on Bayer's own announcement and on court-approval reporting from multiple outlets. Social-media posts are treated only as sentiment signals.
The settlement in numbers
| Parameter | Value | Source |
|---|---|---|
| Announcement date | 17 February 2026 | Bayer |
| Court approval | 20 November 2026 (Missouri judge) | Newsquawk |
| Maximum total | $7.25 billion | Bayer |
| Payment profile | Declining, capped annual payments, up to 21 years | Bayer |
| Individual awards | Average of $10,000 to $165,000 depending on use, age at diagnosis and severity | ClickOrlando (AP) |
| Variation around the average | 80% to 120% per court filings | The New Lede |
| Attorneys' fees | $600 million | ABC7 |
Two features matter for risk managers. First, the structure covers plaintiffs alleging exposure before 17 February 2026, which bounds the future-claims population by a date rather than leaving it open-ended [Bayer via BusinessWire]. Second, the settlement agreements contain no admission of liability or wrongdoing [Bayer via BusinessWire].
Premium Content
This article is for Premium subscribers. Access in-depth analyses, exclusive data and strategic recommendations.
- US judge approves Bayer’s (BAYN GY) USD 7.25bln Roundup settlement | Newsquawk
- Monsanto litigation: Bayer reaches settlement agreement, denies wrongdoing
- Missouri judge approves Bayer's $7.25 billion Roundup settlement
- Court Approves $7.25B Settlement With Bayer Over Claims Roundup Caused Cancer
- Bayer proposes $7.25B plan to settle Roundup cancer ...
- C_202500741EN.000101.fmx.xml
- sec-gov-archives-edgar-data-30554-000175567226000025-r75-htm
- Commitments and Contingencies
- Court approves $7.25 billion settlement with Bayer over claims Roundup weed killer caused cancer - ABC7 San Francisco
- Court approves $7.25 billion settlement with Bayer over claims Roundup weed killer caused cancer
- US$7.25 billion settlement over Roundup weed killer cancer claims
- Court approves $7.25 billion settlement with Bayer over claims Roundup weed killer caused cancer - Breitbart
- Court approves $7.25B settlement with Bayer over claims Roundup weedkiller caused cancer
- Bayer proposes $7.25 billion class action settlement in Roundup litigation - The New Lede
- Bayer sees flat 2026 profits amid settlement efforts over Roundup claims
- FinancialContent - Bayer's $7.25 Billion Roundup Settlement: A 21-Year Plan for Certainty
- Bayer Aktiengesellschaft: Monsanto announces Roundup™ class settlement agreement to resolve current and future claims
- Monsanto announces Roundup™ class settlement agreement to resolve current and future claims
- bayer increases roundup litigation provisions by 1 37 billion ce7c5fd2d980fe20
- www.businesswire.com
- Monsanto announces Roundup™ class settlement agreement to
- Court approves $7.25 billion settlement with Bayer over claims Roundup weed killer caused cancer - ABC7 San Francisco
- Court approves $7.25 billion settlement with Bayer over claims Roundup weed killer caused cancer
- US$7.25 billion settlement over Roundup weed killer cancer claims
- Court approves $7.25 billion settlement with Bayer over claims Roundup weed killer caused cancer - Breitbart
- Court approves $7.25B settlement with Bayer over claims Roundup weedkiller caused cancer
- Bayer proposes $7.25 billion class action settlement in Roundup litigation - The New Lede
- Bayer /2. €1.2 billion allocated for glyphosate litigation